Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19 (coronavirus disease-19), represents a far more serious threat to public health than SARS and MERS coronaviruses, due to its ability to spread more efficiently than its predecessors. Currently, there is no worldwide-approved effective treatment for COVID-19, urging the scientific community to intense efforts to accelerate the discovery and development of prophylactic and therapeutic solutions against SARS-CoV-2 infection. In particular, effective antiviral drugs are urgently needed. With few exceptions, therapeutic approaches to combat viral infections have traditionally focused on targeting unique viral components or enzymes; however, it has now become evident that this strategy often fails due to the rapid emergence of drug-resistant viruses. Targeting host factors that are essential for the virus life cycle, but are dispensable for the host, has recently received increasing attention. The spike glycoprotein, a component of the viral envelope that decorates the virion surface as a distinctive crown ("corona") and is essential for SARS-CoV-2 entry into host cells, represents a key target for developing therapeutics capable of blocking virus invasion. This review highlights aspects of the SARS-CoV-2 spike biogenesis that may be amenable to host-directed antiviral targeting.
Santopolo, S., Riccio, A., & Santoro, M.G. (2020). The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS.
|Tipologia:||Articolo su rivista|
|Citazione:||Santopolo, S., Riccio, A., & Santoro, M.G. (2020). The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS.|
|Settore Scientifico Disciplinare:||Settore MED/07|
|Revisione (peer review):||Esperti anonimi|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.bbrc.2020.10.080|
|Stato di pubblicazione:||Online ahead of print|
|Data di pubblicazione:||2020|
|Titolo:||The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy|
|Autori:||Santopolo, S; Riccio, A; Santoro, MG|
|Appare nelle tipologie:||01 - Articolo su rivista|